|Day Low/High||15.79 / 15.88|
|52 Wk Low/High||12.41 / 16.70|
If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)
TOKYO and SAN FRANCISCO, Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc.
- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -
Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas
XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy
TOKYO, Aug. 6, 2019 /PRNewswire/ -- Astellas Pharma Inc.
-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-
Glinski to Oversee US Sales for XTANDI
-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-
- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy -
- Data Presented at the American Urological Association 2019 Annual Meeting -
The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.
France's Sanofi said it would move to oust the current board of Medivation if the latter does not engage in discussions about a transaction.
Pfizer reportedly made a bid for the cancer drug maker, rivaling Sanofi's $9.3 billion offer, but analysts say another company might be the best fit.
The San Francisco target rejects the $9.3 billion offer, but biotech growth and a healthy pipeline mean Sanofi isn't desperate for Medivation's cancer treatments.
The French pharmaceuticals company takes its campaign to snare the oncology specialist public.
Shares of Medivation are rallying after Bloomberg reported the company is working with advisers to defend itself against a potential takeover.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.